-
2024-517671-21-00
5
2025-09-30
Coronavirus Disease 2019 (COVID-19)
-
2024-518296-56-00
5
2025-09-29
Crohn’s Disease
-
2024-520386-31-00
5
2025-09-22
Locally Advanced Head & Neck Squamous Cell Carcinoma
-
2024-519814-29-00
4
2025-09-12
Advanced or Metastatic Non-small Cell Lung Cancer
-
2024-512752-38-00
5
2025-09-09
Adjunctive and maintenance treatment to HCT
-
2024-519605-36-00
4
2025-08-08
Melanoma
-
2024-520154-38-00
5
2025-07-29
Acute Myeloid Luekemia
-
2023-510356-23-00
1
2025-07-18
Locally advanced or metastatic unresectable colorectal
cancer (CRC)
-
2023-506887-15-00
4
2025-07-14
Hepatocellular carcinoma
-
2024-516162-11-00
5
2025-07-14
Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
-
2024-518771-66-00
9
2025-07-01
Hepatoblastoma, Rhabdomyosarcoma
-
2024-519015-34-00
1
2025-06-30
Systemic Lupus Erythematosus
-
2024-512412-22-00
5
2025-06-24
Hemolytic Uremic Syndrome
-
2024-514596-18-00
9
2025-06-20
Difficult to treat rheumatoid arthritis
-
2023-510294-34-00
5
2025-06-12
small lymphocytic lymphoma (SLL)
-
2024-515698-85-00
5
2025-06-12
Locally Advanced or Metastatic Non-small Cell Lung Cancer
-
2022-502184-38-00
4
2025-06-06
Rapidly progressive glomerulonephritis
-
2024-517147-31-00
9
2025-05-23
Tumours, Gynecological
-
2024-515526-89-00
4
2025-05-16
Diffuse Large B-Cell Lymphoma (DLBCL)
-
2024-517706-29-00
5
2025-05-13
Ataxia Telangiectasia
-
2023-507030-24-00
4
2025-04-30
Persistent Corneal Epithelial Defects
-
2024-516030-35-00
5
2025-04-30
Multiple myeloma
-
2024-514465-18-00
9
2025-04-23
Advanced or Metastatic Non-Squamous NSCLC
-
2024-516173-76-01
5
2025-04-22
HER2-positive or HER2-low (incl. ultra-low) early breast cancer